Medicamen Biotec Cash flow Statement
Figures in Rs cr
Consolidated Cash Flow Results
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
No of Months
12
12
12
12
12
12
Profit Before Tax
9.00
14.00
14.00
12.00
13.00
12.00
Adjustment
14.00
10.00
10.00
7.00
7.00
7.00
Changes In working Capital
-27.00
-28.00
-17.00
-2.00
-3.00
-11.00
Cash Flow after changes in Working Capital
-3.00
-3.00
7.00
17.00
17.00
8.00
Cash Flow from Operating Activities
-6.00
-6.00
4.00
12.00
12.00
4.00
Cash Flow from Investing Activities
-5.00
-5.00
-8.00
-17.00
-37.00
-14.00
Cash Flow from Financing Activities
6.00
29.00
4.00
5.00
19.00
-3.00
Net Cash Inflow / Outflow
-5.00
16.00
0.00
0.00
-5.00
-14.00
Opening Cash & Cash Equivalents
20.00
3.00
3.00
3.00
8.00
22.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
14.00
20.00
3.00
3.00
3.00
8.00
Compare Cash Flow Results of Medicamen Biotec
Figures in Rs cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
9.49
2399.36
-2,390.00
-99.60%
Adjustment
14.35
212.2
-198.00
-93.24%
Changes In working Capital
-27.52
20.42
-47.00
-234.77%
Cash Flow after changes in Working Capital
-3.68
2631.98
-2,634.00
-100.14%
Cash Flow from Operating Activities
-6.74
2152.45
-2,158.00
-100.31%
Cash Flow from Investing Activities
-5.56
-2080.52
2,075.00
99.73%
Cash Flow from Financing Activities
6.31
5.27
1.00
19.73%
Net Cash Inflow / Outflow
-5.99
77.19
-82.00
-107.76%
Opening Cash & Cash Equivalents
20.78
304.82
-284.00
-93.18%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
14.79
382.01
-368.00
-96.13%
Cash Flow - Snapshot (Consolidated) - Mar'24
YoY Growth in year ended Mar 2024 is -7.15% vs -253.04% in Mar 2023
Mar'24
Mar'23
Change(%)
Cash Flow from Operating Activities
-6.74
-6.29
-7.15%